STAT

Opinion: I handed over my genetic data to the NIH. Here’s why you should, too

I direct the NIH's All of Us Research Program. I believe so strongly in its ability to protect privacy that I've signed up as a participant.
Kenneth Parker Ulrich (left), a research technician at the University of Pittsburgh Medical Center, prepares to collect a blood sample from Erricka Hager, a participant in the NIH's All of Us Research Program.

The National Institutes of Health recently launched the All of Us Research Program to create one of the largest, richest public resources for biomedical research in human history. Its mission is to accelerate medical breakthroughs that personalize prevention, treatment, and care for all Americans. As the director of this unprecedented program — and as a cancer survivor, patient advocate, and participant in more than a dozen research studies — I want to share how we are safeguarding participant confidentiality and personal data.

Long before this program began, the NIH conducted focus groups, , and set up listening sessions with people about their hopes, ideas, and concerns about collecting detailed and sensitive health information over their lifetimes. We made certain to meet with . These communities have good reason to be suspicious of research because of past breaches of trust perpetrated by government programs — from the Tuskegee syphilis study to the Havasupai genetic study. With their help and input from top privacy, security, and ethics experts, we created clear and principles for All of Us and included these .

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks